In the world of peptide research, few synthetic constructs have garnered as much attention as the padre peptide sequence. As a user who frequently interacts with various synthetic compounds for laboratory study, I have found that understanding the structural integrity an A third vaccination with a single T cell epitope confers d the specific biochemical profile of this molecule is essential for anyone looking into immunological research models.
Defining the PADRE Peptide
The PADRE (Pan-DR-binding epitope) is a synthetic, 13-amino acid peptide that has become a staple in modern investigative workflows. Its primary appeal lies in its function as a universal peptidic epitope. Unlike naturally occurring sequences that may show restricted binding, the PADRE peptide was specifically engineered for promiscuous binding to multiple HLA class II DR alleles.
When I look at the technical specifications, the sequence: AKFVAAWTLKAAA is the gold standard for this molecule. This specific arrangement—Ala-Lys-Phe-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-Ala—is often referenced in literature as a vital tool for those studying T-cell help.
Technical Specifications and Synthesis
For those involved in sourcing, it is important to verify the purity and chemical structure of the compound. The H-AKFVAAWTLKAAA-OH configuration i I-Ab | synthetic epitope PADRE | AKFVAAWTLKAA s standard, and high-quality preparations typically boast a purity of >95% via HPLC/MS.
Key attributes I look for include:
* Molecular Weight: Approximately 1347.61 g/mol.
* Formula: C65H102N16O15.
* Structure: It is a linear sequence, though some advanced designs incorporate modifications like D-alanine, L-cyclohexylalanine, and aminohexanoic acid to enhance stability or binding affinity.
Insights into the PADRE Sequence
The PADRE sequence (AKFVAAWTLKAAA) is widely utilized because it provides a consistent pan-DR epitope (PADRE) peptide framework. In by MF del Guercio·1997·Cited by 144—The 33-residuePADRE-PVB linear constructs were highly immunogenic and induced responses comparable to those obtained with the multiple antigen peptides (MAP) Read more my experience reviewing various protocols, the AKFVAAWTLKAA variant is sometime by MF del Guercio·1997·Cited by 144—The 33-residuePADRE-PVB linear constructs were highly immunogenic and induced responses comparable to those obtained with the multiple antigen peptides (MAP) Read more s discussed, but the 13-amino acid version remains the most frequent point of reference.
When researchers discuss pan-DR epitopes (PADRE) peptides, they are often highlighting how these molecules act as a bridge. For ins by IN Pardieck·2022·Cited by 59—Here we show that a three dose regimen of a syntheticpeptidevaccine elicits an accruing CD8 + T cell response against one SARS-CoV-2 Spike epitope.Read more tance, I have noted studies where two copies of Aβ1–11 fused with the promiscuous nonself T cell epitope, PADRE were used to explore specific molecular interactions. This illustrates the versatility of the PADRE construct; it is not just a standalone molecule but a modular component that can be fused to other sequences, such as HA epitope 1 - HA epitope 2 - M epitope 9, to create complex, multi-epitope constructs.
Practical Observations
In laboratory settings, the peptide is often handled as a lyophilized powder. Whether you are working with a PADRE peptides mix formulated with IFA or exploring a pan HLA-DR epitope (PADRE) in a custom vaccine design, the stability of the 13 amino acid nonnatural pan DR epitope (PADRE) is a significant advantage.
The PADRE is a universal synthetic 13 amino acid peptide that continues to be a subject of fascination due to its ability to activate specific cellular responses. If The PADRE sequence (AKFVAAWTLKAAA) is a universal helper T cell epitope capable of binding to various HLA-DR molecules, activating CD4 + T cell immune responses Read more you are examining the padre peptide, ens by I Petrushina·2007·Cited by 136—Here, we describe a second generation epitope vaccine composed oftwo copies of Aβ1–11 fused with the promiscuous nonself T cell epitope, PADRERead more ure that the documentation confirms the sequence: AKFVAAWTLKAAA precisely, as variations in the C-terminus or N-terminus can influence experimental outcomes.
Conclusion
Whether you are a seasoned researcher or just beginning to explore the utility of synthetic epitopes, the PADRE peptide offers a reliable, well-characterized scaffold. By focusing on the AKFVAAWTLKAAA sequence and adhering to rigorous handling standards, one can effectively utilize this epi-based tool to further investigate the complexities of immune recognition and peptide-MHC interactions. Always prioritize sourcing from vendors who provide clear HPLC/MS data to ensure your padre peptide meets the necessary criteria for your specific research goals.